Inactive Instrument

HedgePath Pharmaceuticals Inc Share Price

US42278K1025

Biotechnology & Medical Research

Press Releases: HedgePath Pharmaceuticals Inc

19/08/19	HedgePath Pharmaceuticals : Announces Name Change to INHIBITOR Therapeutics, Inc. and Ticker Symbol Change to "INTI" Effective August 20, 2019	PR
07/03/19	HedgePath Pharmaceuticals : Provides Corporate Update for the Fourth Quarter and Year End 2018	PR
09/07/18	HedgePath Pharmaceuticals : Closes Second Tranche of Mayne Pharma Financing	PR
14/05/18	HedgePath Pharmaceuticals : Announces Expanded Patent Coverage	PR
11/01/18	HedgePath Pharmaceuticals : Secures New Funding from Mayne Pharma to Support BCCNS Clinical and Regulatory Approval Programs	PR

More press releases

Managers and Directors: HedgePath Pharmaceuticals Inc

Manager	Title	Age	Since
Francis O'Donnell CEO	Chief Executive Officer	76	12/12/2022
James McNulty DFI	Director of Finance/CFO	76	12/12/2022
Simon Bettink COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Francis O'Donnell CHM	Chairman	76	12/12/2022
Niraj Vasisht BRD	Director/Board Member	62	12/12/2022
Samuel Sears BRD	Director/Board Member	82	01/08/2013

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HEDGEPATH PHARMACEUTICALS INC	-27.42%	-3.08%	-	-	32.23M
WUXI APPTEC CO., LTD.	-4.83%	+2.88%	+55.87%	+69.12%	69.4B
ARGENX SE	+0.02%	+1.42%	+12.77%	+75.21%	57.24B
LONZA GROUP AG	-1.34%	+3.53%	+23.22%	+101.58%	57.62B
IQVIA HOLDINGS INC.	+2.62%	-1.17%	+29.37%	+37.84%	43.65B
BEONE MEDICINES AG	+5.09%	+9.53%	+26.62%	+121.44%	44.03B
REVOLUTION MEDICINES, INC.	+8.24%	+1.06%	+224.03%	+767.69%	38.08B
CELLTRION, INC.	-1.86%	+11.46%	+26.67%	+61.40%	36.31B
GENMAB A/S	-2.97%	-6.89%	+91.79%	+74.60%	32.61B
WUXI BIOLOGICS (CAYMAN) INC.	-2.18%	+5.68%	+36.21%	-0.69%	25.47B
Average	-2.46%	+2.24%	+58.51%	+145.36%	44.93B
Weighted average by Cap.	+0.05%	+2.44%	+53.94%	+138.05%

See all sector performances

HedgePath Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics for patients with certain cancers. The Company may also explore acquiring or licensing other therapeutics addressing unmet needs and orphan indications beyond cancer. The Company's preliminary focus is on the development of therapies for skin, lung and prostate cancers in the United States, with an indication targeting basal cell carcinoma (BCC) in patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS, also known as Gorlin Syndrome). As of December 31, 2016, the Company was engaged in conducting an open label, Phase IIb clinical trial of a therapy for BCCNS. The Company's therapy is based upon super bioavailability (SUBA)-Itraconazole, an oral formulation of the marketed anti-fungal drug, itraconazole.

Employees

Sector

Biotechnology & Medical Research

More about the company